G20 G30
Conditions
Interventions
Group 1: 200 subjects have unipolar depression or dysthymia
Group 2: 200 from a REM sleep disorder
Group 3: 200 from an idiopathic disorder of smell perception
Group 4: 200 subjects had and did not ha
Sponsors
Universitätsklinikum Tübingen
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: Ability to give consent and a written declaration of consent, depression cohort: Depressive episode or dysthymia (currently BDI <25 and CES-D <12 or in the last 10 years) according to the criteria of ICD 10 or DSM IV. REM sleep disorder cohort: Presence of the minimum requirements for diagnosis (1. Movement of the legs or body associated with dream activity, and 2. one of the following 3 criteria: (potentially) dangerous sleep behavior, “living out dreams”, interruption of sleep continuity) (ICSD, 2001 ): Testing by questionnaire. Cohort with idiopathic disturbance of smell perception: history of reduced smell perception in the past years, pathological smell test. Cohort of symptom-free subjects: All three symptoms are excluded both by taking a medical history and by the tests mentioned above.
Exclusion criteria
Exclusion criteria: Any impairment that prevents the test person from giving his or her independent consent. Other diseases that make it impossible for the study participant to perform the necessary tasks within the scope of the study or to communicate with the study doctor. Classic neuroleptics or valproate have been taken in the last 3 months or a history of taking over 3 months. History of addiction. Benzodiazepam intake of more than the equivalent dose of 1.5 mg lorazepam. Cognitive deficits that cannot be explained by the existing symptoms (e.g. depression). Dementia, immobility (care level> 1), concrete move plans in the region outside of Baden-Württemberg.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. to determine the prevalence of risk factors, vulnerability factors, and preclinical markers in a risk population for IPS and AD defined by the presence of at least ONE preclinical symptom (either depression, REM sleep disorder, or odor disorder). Depression and REM sleep disorder will be done through the use of published screening questionnaires. Olfactory disorder is diagnosed using a smell test (Sniffin Sticks). IPS is diagnosed by a neurological specialist using the UPDRS and a neurological examination. A neuropsychological test battery (CERAD) is used to screen for AD. Diagnosis is then made by a geriatric psychiatrist, and a neural fluid test for biomarkers is used to confirm diangosis. 2. quantitative statement from a prospective study design about the frequency of occurrence of IPS and AD in cohorts with either "depression," "REM sleep disorder," or "idiopathic odor perception disorder" (number of "converters") 3. quantitative statement on the frequency of occurrence of IPS and AD in the presence of multiple risk factors/preclinical markers/vulnerability factors (odds ratio) versus only one such factor (odds ratio). 4. retrospective comparison of the collected data "converters to IPS or AD" versus "non-converters" (cluster annalsysis, group comparison) with the aim of defining further risk characteristics or preclinical markers 5. explorative longitudinal analysis of symptoms in neurodegenerative patients, also in relation to the initially existing risk factors "depression", "REM sleep disorder" or "idiopathic olfactory perception disorder", and further known and collected risk factors (keyword endophenotype) | — |
Countries
Germany
Contacts
Public ContactAnna-Katharina von Thaler
Neurologische KlinikUniversitätsklinikum Tübingen
Outcome results
None listed